Protein and Oligonucleotide LC-MS

Oligonucleotides, aptamer-drug-conjugates (ApDCs), antibody-oligonucleotide conjugates (AOCs) and mRNA drugs/vaccines are polyanionic large molecules. Their bioanalysis is extremely challenging from sample preparation to instrument analysis. Some of Resolian’s core team members have worked on the regulated bioanalysis of oligonucleotides since 2006.

Resolian has established six most commonly used bioanalytical technology platforms (see below) to support the ADME and PK/PD studies of oligonucleotide therapeutics/conjugates in different research and development stages, from early in vitro drug screening to IND/NDA filing studies.

Additionally, Resolian has developed three different assay platforms (two step assay, sandwich assay and bridging assay) to evaluate the ADA of oligonucleotide therapeutics.

Reach out to us directly to learn more about Resolian’s Protein and Oligonucleotide LC-MS services.